TY - JOUR
T1 - Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis
AU - Mizutani, Satoshi
AU - Kodera, Hitoshi
AU - Sato, Yoshiko
AU - Nanki, Toshihiro
AU - Yoshida, Shunji
AU - Yasuoka, Hidekata
N1 - Publisher Copyright:
© 2020, International League of Associations for Rheumatology (ILAR).
PY - 2021/1
Y1 - 2021/1
N2 - Objectives: Iguratimod (IGU) is a conventional synthetic disease-modifying drug that has been approved based on its additive effects with methotrexate (MTX) for the treatment of rheumatoid arthritis (RA). The objective of the study is to establish the effectiveness of IGU with versus IGU without MTX irrespective of whether MTX is well tolerated or not by the patients. Methods: Disease activity scores in 177 RA patients treated using IGU were retrospectively evaluated at baseline and after 4, 12, and 24 weeks, and adverse events (AEs) were noted. Results: IGU reduced the disease activity parameters, disease activity score (DAS)-ESR, DAS-CRP, the simplified disease activity index (SDAI), and clinical disease activity index (CDAI) in the concomitant MTX and non-MTX, female and male, and young and elderly patient groups after 24 weeks. Multivariate analysis demonstrated that IGU was more effective with concomitant MTX and in elderly and male patients. Severe AEs were observed only in the elderly group: two cases of pneumonia, 1 of pneumocystis pneumonia, 1 of heart failure, and 1 of salivary gland adenoma. Conclusions: IGU is effective for RA, especially with concomitant MTX, and in elderly and male patients.
AB - Objectives: Iguratimod (IGU) is a conventional synthetic disease-modifying drug that has been approved based on its additive effects with methotrexate (MTX) for the treatment of rheumatoid arthritis (RA). The objective of the study is to establish the effectiveness of IGU with versus IGU without MTX irrespective of whether MTX is well tolerated or not by the patients. Methods: Disease activity scores in 177 RA patients treated using IGU were retrospectively evaluated at baseline and after 4, 12, and 24 weeks, and adverse events (AEs) were noted. Results: IGU reduced the disease activity parameters, disease activity score (DAS)-ESR, DAS-CRP, the simplified disease activity index (SDAI), and clinical disease activity index (CDAI) in the concomitant MTX and non-MTX, female and male, and young and elderly patient groups after 24 weeks. Multivariate analysis demonstrated that IGU was more effective with concomitant MTX and in elderly and male patients. Severe AEs were observed only in the elderly group: two cases of pneumonia, 1 of pneumocystis pneumonia, 1 of heart failure, and 1 of salivary gland adenoma. Conclusions: IGU is effective for RA, especially with concomitant MTX, and in elderly and male patients.
UR - http://www.scopus.com/inward/record.url?scp=85086106869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086106869&partnerID=8YFLogxK
U2 - 10.1007/s10067-020-05208-y
DO - 10.1007/s10067-020-05208-y
M3 - Article
C2 - 32506311
AN - SCOPUS:85086106869
SN - 0770-3198
VL - 40
SP - 123
EP - 132
JO - Clinical Rheumatology
JF - Clinical Rheumatology
IS - 1
ER -